Independent directory Public ClinicalTrials.gov records United States
Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 18, 2026, 11:37 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 385–408 of 676 matching trials from the live ClinicalTrials.gov search.
Conditions
Aortic Valve Stenosis
Interventions
Ataciguat, Placebo
Drug
Lead sponsor
Jordan D. Miller, Ph.D.
Other
Eligibility
50 Years and older
Enrollment
44 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2015
U.S. locations
1
States / cities
Rochester, Minnesota
Conditions
Ethics, Cardiac Rehabilitation, Coronary Heart Disease (CHD), Heart Failure, Percutaneous Coronary Intervention (PCI), Aortic Valve Replacement, Myocardial Infarction (MI)
Interventions
Usual Care Group, More Support and Tools
Behavioral
Lead sponsor
Baystate Medical Center
Other
Eligibility
18 Years and older
Enrollment
160 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
1
States / cities
Springfield, Massachusetts
Conditions
Hypertrophic Cardiomyopathy, Left Ventricular Outflow Obstruction, Systolic Anterior Motion
Interventions
SESAME Procedure
Device
Lead sponsor
National Heart, Lung, and Blood Institute (NHLBI)
NIH
Eligibility
21 Years to 100 Years
Enrollment
200 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2030
U.S. locations
8
States / cities
Washington D.C., District of Columbia • Atlanta, Georgia • Boston, Massachusetts + 5 more
Conditions
Chronic Symptomatic Functional Tricuspid Regurgitation, Tricuspid Valve Insufficiency, Heart Valve Disease
Interventions
Mitralign Percutaneous Tricuspid Valve Annuloplasty System (PTVAS)
Device
Lead sponsor
Mitralign, Inc.
Industry
Eligibility
18 Years to 85 Years
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2019
U.S. locations
11
States / cities
Los Angeles, California • San Francisco, California • Washington D.C., District of Columbia + 8 more
Conditions
Aortic Valve Stenosis
Interventions
Pre-habilitation
Other
Lead sponsor
WellSpan Health
Other
Eligibility
Not listed
Enrollment
35 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2021
U.S. locations
1
States / cities
York, Pennsylvania
Conditions
Aortic Stenosis, LV Remodeling, Hypertrophy
Interventions
Tadalafil, Placebo
Drug
Lead sponsor
Washington University School of Medicine
Other
Eligibility
18 Years and older
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2017
U.S. locations
1
States / cities
St Louis, Missouri
Conditions
Coronary Artery Disease, Coronary Artery Stenoses, Valve Regurgitation, Mitral, Valve Regurgitation, Tricuspid
Interventions
Exparel Injectable Product, Bupivacaine Hydrochloride
Drug
Lead sponsor
Kathirvel Subramaniam
Other
Eligibility
18 Years and older
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2020
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Conditions
Heart Defects, Congenital, Tetralogy of Fallot, Pulmonary Valve Insufficiency, Pulmonary Valve Stenosis
Interventions
GORE PV1
Device
Lead sponsor
W.L.Gore & Associates
Industry
Eligibility
5 Years and older
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2030
U.S. locations
3
States / cities
Chicago, Illinois • Boston, Massachusetts • Columbus, Ohio
Completed No phase listed Observational

The Bronx-Valve Registry

NCT05453526
Conditions
Valvular Heart Disease
Interventions
Not listed
Lead sponsor
Montefiore Medical Center
Other
Eligibility
18 Years and older
Enrollment
330,570 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2019
U.S. locations
1
States / cities
The Bronx, New York
Conditions
Aortic Valve Stenosis
Interventions
V8 Balloon Aortic Valvuloplasty (BAV) Catheter
Device
Lead sponsor
InterValve, Inc.
Industry
Eligibility
Not listed
Enrollment
103 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2015
U.S. locations
7
States / cities
Los Angeles, California • Minneapolis, Minnesota • Nashville, Tennessee + 2 more
Conditions
Mitral Regurgitation
Interventions
MR-ace Implant and Delivery System
Device
Lead sponsor
Polares Medical SA
Industry
Eligibility
21 Years and older
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2032
U.S. locations
3
States / cities
Atlanta, Georgia • The Bronx, New York • Cincinnati, Ohio
Conditions
Obstructive Hypertrophic Cardiomyopathy (oHCM)
Interventions
Aficamten (CK-3773274) (5 mg, 10 mg, 15 mg and 20 mg), Placebo to match aficamten, Metoprolol succinate (50 mg, 100 mg, 150 mg and 200 mg), Placebo to match metoprolol succinate
Drug
Lead sponsor
Cytokinetics
Industry
Eligibility
18 Years to 85 Years
Enrollment
175 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2025
U.S. locations
28
States / cities
Anchorage, Alaska • Phoenix, Arizona • La Jolla, California + 21 more
Recruiting No phase listed Observational Accepts healthy volunteers

Defining the Brain Phenotype of Children With Williams Syndrome

NCT01132885
Conditions
Williams Syndrome, Duplication
Interventions
Not listed
Lead sponsor
National Institute of Mental Health (NIMH)
NIH
Eligibility
5 Years to 99 Years
Enrollment
415 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
Started 2011
U.S. locations
1
States / cities
Bethesda, Maryland
Conditions
Hypertrophic Cardiomyopathy
Interventions
Eleclazine, Placebo
Drug
Lead sponsor
Gilead Sciences
Industry
Eligibility
18 Years to 65 Years
Enrollment
172 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2017
U.S. locations
26
States / cities
Los Angeles, California • Stanford, California • New Haven, Connecticut + 16 more
Conditions
Congestive Heart Failure, Ischemic Cardiomyopathy, Mitral Valve Prolapse, Mitral Regurgitation, Aortic Valve Disease, Tricuspid Regurgitation
Interventions
Not listed
Lead sponsor
Woolsthorpe Technologies, LLC
Industry
Eligibility
18 Years to 95 Years
Enrollment
54 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008
U.S. locations
3
States / cities
Nashville, Tennessee • Houston, Texas
Active, not recruiting No phase listed Observational Results available

MitraClip EXPAND G4 Study

NCT04177394
Conditions
Mitral Valve Regurgitation, Mitral Regurgitation
Interventions
MitraClip G4 System
Device
Lead sponsor
Abbott Medical Devices
Industry
Eligibility
Not listed
Enrollment
1,164 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2028
U.S. locations
24
States / cities
Birmingham, Alabama • Mobile, Alabama • Little Rock, Arkansas + 20 more
Conditions
Aortic Valve Stenosis
Interventions
Transcatheter Aortic Valve Replacement
Procedure
Lead sponsor
The Society of Thoracic Surgeons
Other
Eligibility
18 Years and older
Enrollment
16,000 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2035
U.S. locations
1
States / cities
Washington D.C., District of Columbia
Conditions
Mitral Regurgitation
Interventions
No intervention - registry
Other
Lead sponsor
Abbott Medical Devices
Industry
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2017
U.S. locations
8
States / cities
Phoenix, Arizona • Los Angeles, California • Aurora, Colorado + 5 more
Conditions
Obstructive Hypertrophic Cardiomyopathy
Interventions
mavacamten, Placebo
Drug
Lead sponsor
MyoKardia, Inc.
Industry
Eligibility
18 Years and older
Enrollment
251 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2020
U.S. locations
29
States / cities
Scottsdale, Arizona • Los Angeles, California • San Francisco, California + 23 more
Conditions
Tetralogy of Fallot, Ventricular Tachycardia, Sudden Cardiac Death
Interventions
Electroanatomic substrate mapping
Diagnostic Test
Lead sponsor
Boston Children's Hospital
Other
Eligibility
Not listed
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2024
U.S. locations
1
States / cities
Boston, Massachusetts
Active, not recruiting Not applicable Interventional Results available

PARTNER 3 Trial - Mitral Valve in Valve

NCT03193801
Conditions
Mitral Valve Insufficiency, Mitral Valve Disease, Mitral Valve Regurgitation, Heart Failure
Interventions
Edwards SAPIEN 3 transcatheter valve, Model 9600TFX
Device
Lead sponsor
Edwards Lifesciences
Industry
Eligibility
Not listed
Enrollment
53 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2031
U.S. locations
9
States / cities
Atlanta, Georgia • Chicago, Illinois • Evanston, Illinois + 6 more
Completed No phase listed Observational Accepts healthy volunteers

UTSW HP [13-C] Pyruvate Injection in HCM

NCT03057002
Conditions
Cardiomyopathy, Hypertrophic, Dilated Cardiomyopathy, Duchenne Muscular Dystrophy, Cardiac Sarcoidosis, Becker Muscular Dystrophy, Heart Failure With Preserved Ejection Fraction, Heart Failure With Reduced Ejection Fraction
Interventions
Hyperpolarized 13C-Pyruvate
Diagnostic Test
Lead sponsor
University of Texas Southwestern Medical Center
Other
Eligibility
18 Years to 60 Years
Enrollment
7 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2023
U.S. locations
1
States / cities
Dallas, Texas
Conditions
Mitral Valve Regurgitation
Interventions
Caisson TMVR System
Device
Lead sponsor
Caisson Interventional LLC
Industry
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2023
U.S. locations
13
States / cities
Los Angeles, California • Washington D.C., District of Columbia • Delray Beach, Florida + 9 more
Active, not recruiting No phase listed Observational

ALTERRA Post-Approval Study

NCT05378386
Conditions
Pulmonary Valve Insufficiency, Complex Congenital Heart Defect, Tetralogy of Fallot, Pulmonary Regurgitation, RVOT Anomaly
Interventions
Edwards Alterra Adaptive Prestent with SAPIEN 3 Transcatheter Pulmonary Valve System
Device
Lead sponsor
Edwards Lifesciences
Industry
Eligibility
Not listed
Enrollment
150 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2035
U.S. locations
23
States / cities
Birmingham, Alabama • Little Rock, Arkansas • Los Angeles, California + 18 more